Shi Yujie, Zhao Zongmin, Peng Kevin, Gao Yongsheng, Wu Debra, Kim Jayoung, Mitragotri Samir
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, P. R. China.
Adv Healthc Mater. 2021 Jan;10(2):e2001455. doi: 10.1002/adhm.202001455. Epub 2020 Nov 17.
Ionic liquids (ILs) possess unique solvation and biological properties for drug delivery. Choline and geranic acid (CAGE) in particular, has been successfully formulated to orally deliver insulin and hydrophobic therapeutics such as sorafenib (SRF). However, relatively little is known about the effect of CAGE on intracellular delivery of drugs. Here the effect of low-concentration CAGE (<2 mg mL ) on the delivery of SRF into cancer cells (4T1, PANC-1, and HT29) as well as intestine epithelium cells (Caco-2) is studied. The anti-cancer effect of SRF is enhanced by up to fivefold in the presence of CAGE (0.5 mg mL ). The effect is mediated not by enhancing the cellular uptake of SRF but by improving intracellular SRF retention by inhibiting exocytosis. Moreover, CAGE improves the anti-tumor effect of SRF by increasing apoptosis and blocking cell-cycle progression. Moreover, CAGE significantly enhances the penetration of SRF into and across multicellular constructs with multiple mechanisms involved. Collectively, the administration of ILs such as CAGE combined with SRF may offer a novel therapy to better inhibit tumor progression.
离子液体(ILs)在药物递送方面具有独特的溶剂化和生物学特性。特别是胆碱和香叶酸(CAGE),已成功用于口服递送胰岛素和索拉非尼(SRF)等疏水性治疗药物。然而,关于CAGE对药物细胞内递送的影响,人们了解得相对较少。在此,研究了低浓度CAGE(<2 mg/mL)对SRF递送至癌细胞(4T1、PANC-1和HT29)以及肠上皮细胞(Caco-2)的影响。在CAGE(0.5 mg/mL)存在的情况下,SRF的抗癌效果提高了五倍。这种效果不是通过增强SRF的细胞摄取来介导的,而是通过抑制胞吐作用来改善细胞内SRF的保留。此外,CAGE通过增加细胞凋亡和阻断细胞周期进程来提高SRF的抗肿瘤效果。此外,CAGE通过多种机制显著增强SRF进入和穿过多细胞构建体的渗透能力。总体而言,给予CAGE等离子液体与SRF联合使用可能提供一种更好地抑制肿瘤进展的新疗法。
Adv Healthc Mater. 2021-1
J Control Release. 2020-6-10
Adv Mater. 2019-5-21
ACS Biomater Sci Eng. 2023-6-12
Adv Healthc Mater. 2021-7
J Control Release. 2018-7-17
Int J Pharm. 2012-10-30
AAPS PharmSciTech. 2016-8
J Biomed Mater Res A. 2023-5
Adv Healthc Mater. 2025-7-9
Environ Health (Wash). 2024-7-26
Adv Sci (Weinh). 2021-9